Royalty Report: Drugs, Cancer, Antibody – Collection: 67226


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Cancer
  • Antibody

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 67226

License Grant
In August 2005, the original Licensor entered into a collaboration with the Licensee to humanize the Licensors Sphingomab monoclonal antibody.  In 2014,  the original Licensors rights and obligations pursuant to the Agreement with the Licensee were transferred to the new Licensor, by means of a Deed of Novation. The drug is for the treatment of cancer, as a second-line therapy to treat patients with locally advanced, recurrent cancer.
License Property
Humanization under this agreement with the original Licensor involves utilizing proprietary processes for the purpose of modifying Sphingomab antibodies originally contained in mice for potential human acceptance in a clinical trial. The humanized version of Sphingomab that was produced from the collaboration is called Sonepcizumab.
Field of Use
The Licensee could owe the new Licensor certain additional contingent amounts when drug candidates based on Sonepcizumab pass through the levels of the FDA drug review and approval process.

IPSCIO Record ID: 279345

License Grant
The English Licensor hereby grants to the English Licensee (i) a non-exclusive worldwide sublicense, with the right to grant further Sublicenses, under the Licensed Patent Rights to make, have made, use, import, offer for sale, and/or sell Licensed Products; and (ii) an exclusive worldwide license, with the right to grant Sublicenses, under the Licensor IP to make, have made, use, import, offer for sale, and/or sell Licensed Products.
License Property
US Patent #5,225,539 – Recombinant altered antibodies and methods of making altered antibodies

Licensed Product shall mean a product comprising a Humanized Antibody, the manufacture, use, offer for sale, sale, or importation of which by an unlicensed third party would infringe one or more Valid Claims of the Licensed Patent Rights, or which incorporates Licensor IP or Licensor Inventions.  The term “Licensed Product” does not include chimeric antibodies or murine antibodies.

Humanized Antibody shall mean an antibody that binds to Sphingosine-1-phosphate and is made by Licensor under this Agreement, the antibody comprising murine complementarity determining regions derived from Sphingomabâ„¢ together with human framework regions, and any modifications thereof.

Licensor IP shall mean (i) any Licensor Invention and (ii) all patented and non-patented proprietary technology and information, in any form whatsoever, that is (a) necessary or useful for making and using the Licensed Products, without regard to whether or not the technology or information is patentable; (b) owned, controlled, or developed by Licensor, as of the Effective Date or hereafter during the term of this Agreement; and (c) provided by Licensor to Licensee hereunder, including, but not limited to discoveries, formulae, materials, practices, methods, knowledge, know-how, processes, trade secrets, ideas, concepts, manufacturing, engineering, standard operating procedures, flow diagrams and charts, quality assurance, quality control data, technical data, manufacturing technology, research data and records, and all other confidential or proprietary technical and business information relating to the humanization of murine antibodies, generation of chimeric antibodies, or any gene expression vectors used in such methods and all improvements or modifications thereto.  For purposes of clarity, Licensor IP includes Licensor Inventions that satisfy (a), (b) and (c), above, while Licensor IP does not include Licensed Patent Rights as defined hereunder.

Licensor Invention shall mean any discovery or invention to the extent (i) made or conceived or reduced to practice by or on behalf of Licensor in the performance of the humanization of Licensees Sphingomabâ„¢ antibody under this Agreement, whether or not patentable, and (ii) covering only generally applicable methods or techniques for humanizing antibody proteins or for constructing a vector or reagent used to humanize or express an antibody.

Field of Use
Licensee’s lead product candidate, Sphingomab™, is a monoclonal antibody (mAb) against sphingosine-1-phosphate (S1P), an innovative and validated cancer target.

Sphingomabâ„¢ is the original mouse version of this monoclonal antibody.

IPSCIO Record ID: 386935

License Grant
The parties collaborated to create and develop bispecific antibodies using Licensor’s DuoBody technology platform.

Under this original agreement, Licensee had the right to use the DuoBody technology to create panels of bispecific antibodies (up to 10 DuoBody programs) to multiple disease target combinations.

Licensee received approval from the FDA for amivantamab, as RYBREVANT, a therapy that was created using Danish Licensor’s proprietary DuoBody bispecific technology platform.

License Property
Amivantamab has been approved in the United States and the European Union under the name RYBREVANT for the treatment of certain adult patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with epidermal growth factor receptor (“EGFR”) exon 20 insertion mutations. The two antibody libraries used to produce amivantamab were both generated by Licensor. The antibody pair used to create amivantamab was selected in collaboration between the parties.
Field of Use
The rights grants is used for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. Amivantamab, created using Licensor’s DuoBody technology platform is a fully human bispecific antibody that targets EGFR and Met, two validated cancer targets.

IPSCIO Record ID: 332563

License Grant
The Chinese Licensor and U.S. Licensee, by this collaboration is for the development and commercialization of toripalimab, Licensor’s anti-PD-1 antibody, in the United States and Canada. Upon satisfaction of closing conditions, The Parties will co-develop toripalimab, and Licensee will be responsible for all commercial activities in the licensed territory.

Under the terms of the agreement, Licensee will also be granted options to Licensor’s TIGIT-targeted antibody and next generation engineered IL-2 cytokine for evaluation as potential combination therapies with toripalimab, as well as certain negotiation rights to two early-stage checkpoint inhibitor antibodies.

JS006, an antibody targeting TIGIT.

JS018, a next-generation engineered IL-2 cytokine

Two additional undisclosed early-stage novel immuno-oncology drug candidates.

License Property
Toripalimab is a Chinese domestic anti-PD-1 monoclonal antibody, also approved for the second-line treatment of patients with unresectable or metastatic melanoma, and, supplemental NDAs of toripalimab for the third-line treatment of recurrent/ metastatic nasopharyngeal carcinoma and second-line treatment of metastatic urothelial carcinoma.

JS006 is an antibody targeting TIGIT, a clinically validated immune inhibitory checkpoint. Anti-TIGIT antibodies have demonstrated synergistic anti-tumor activity in combination with anti-PD-1 antibodies.

JS018 is a next-generation engineered IL-2 cytokine designed to inhibit stimulation of regulatory T cells while retaining stimulatory activity on effector T cells and natural killer (“NK”) cells. The option to JS018 is exercisable prior to initiation of Phase 2 clinical development.

Field of Use
This transaction expands Licensees late-stage pipeline into the rapidly growing checkpoint inhibitor market and in oncology with biosimilars.

By this Collaboration, the Parties plan to file additional toripalimab BLAs with the FDA over the next three years for multiple rare and highly prevalent cancers, including non-small cell lung cancer (“NSCLC”).

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.